Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

Malta - Ingliż - Medicines Authority

generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - amoxicillin, clavulanic acid - film-coated tablet - amoxicillin 250 mg clavulanic acid 125 mg - antibacterials for systemic use

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - amoxicillin, clavulanic acid - tablet - 50, 12.5 mg/tablet - amoxicillin and enzyme inhibitor - cats, dogs - antibacterial

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - amoxicillin trihydrate 1003,44 mg - eq. amoxicillin 875 mg; clavulanic acid 125 mg - film-coated tablet - 875 mg - 125 mg - clavulanic acid 125 mg; amoxicillin trihydrate 1003.44 mg - amoxicillin and enzyme inhibitor

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sandoz gmbh - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension - 125mg/5ml+ 31,25mg/5ml

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sandoz gmbh - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - powder for oral suspension - 250mg/5ml+ 62,5mg/5ml

Kanada - Ingliż - Health Canada

apotex inc - amoxicillin (amoxicillin trihydrate); clavulanic acid (clavulanate potassium) - tablet - 250mg; 125mg - amoxicillin (amoxicillin trihydrate) 250mg; clavulanic acid (clavulanate potassium) 125mg - aminopenicillins

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

brown & burk uk ltd - amoxicillin (in the form of amoxicillin trihydrate); clavulanic acid (as potassium clavulanate, diluted with microcrystalline cellulose (1:1)) - film-coated tablet - 250 mg/125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

brown & burk ir limited - amoxicillin; clavulanic acid - film-coated tablet - 250 mg/125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor